Skip to main content
TipRanks
Go Ultimate75% OFF

Lumos Diagnostics Holdings Ltd. (LDX) AI Stock Analysis

28 Followers
AU:LDX

Lumos Diagnostics Holdings Ltd.

(ASX:LDX)

Select Model
Rating:42Neutral
Price Target:AUD 0.07▲(1.39% Upside)
Action:reiterated
Date:10/29/26

The overall score is very low, driven primarily by extremely weak technical momentum and negative valuation metrics. The stock is in a deep downtrend and the company is unprofitable. While the balance sheet provides some financial stability, it is insufficient to offset the severe operational losses and poor market sentiment.

Positive Factors
Steady Revenue GrowthRevenue growth across consecutive fiscal years indicates improving commercial traction and suggests the company is expanding demand for its diagnostic offerings. If sustained, this growth can provide a broader base from which operating efficiency and future profitability may develop.
Negative Factors
Persistent Operating and Net LossesRecurring operating and net losses show that revenue growth has not yet translated into sustainable profitability. This weakens retained financial resources, limits self-funded investment capacity, and leaves the business more exposed if commercial execution or funding conditions deteriorate.

Lumos Diagnostics Holdings Ltd. (LDX) vs. iShares MSCI Australia ETF (EWA)

-75%-50%-25%0%25%50%AU:LDX-67.27%EWA+14.75%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
AUD 71.15M
Dividend Yield
―
Average Volume (3M)
1.34M
Price to Earnings (P/E)
-7.5
Beta (1Y)
1.94
Revenue Growth
1.36%
EPS Growth
39.13%
Country
Australia
Employees
29
Sector
Healthcare
Sector Strength
51
Industry
Medical - Specialties

Lumos Diagnostics Holdings Ltd. Business Overview & Revenue Model

Company Description

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company’s products include FebriDx, a point-of-care diagnost...

Lumos Diagnostics Holdings Ltd. Earnings Call Summary

Earnings Call Date:Feb 26, 2026(Q2-2026)|% Change Since:-71.76%|Next Earnings Date:Mar 04, 2027
Earnings Call SentimentPositive

The call was broadly positive: management secured a material exclusive U.S. distribution agreement (USD 317M minimum), completed and submitted the CLIA waiver study while expressing near-term optimism about approval, achieved strong product revenue growth and high gross margins, and materially improved cash flow and adjusted EBITDA versus prior years. Key risks remain including an outstanding CLIA waiver approval (which drives the commercial ramp), continued adjusted EBITDA losses, declines in IP/services revenue timing, and the need for incremental manufacturing capacity and near-term financing actions. Overall, the highlights (large distribution deal, reimbursement, margin improvement, improved cash flow, nondilutive funding and product momentum) outweigh the lowlights tied mainly to timing, conditionality of the waiver, and continued operating losses.

Positive Updates

Secured Major U.S. Distribution Agreement (PHASE)
Signed a 6-year exclusive U.S. distribution agreement for FebriDx with PHASE Scientific that guarantees a minimum of USD 317 million in sales to Lumos over the term; PHASE also paid a USD 1.0 million exclusivity fee recognized in H1 revenue.

Negative Updates

Adjusted EBITDA Still Negative
Adjusted EBITDA loss of USD 1.4 million in H1, so the company remains unprofitable on an adjusted basis despite improvement versus FY24, with ongoing OpEx increases related to trials and U.S. commercial scaling.

Company Guidance

Management guided that CLIA‑waiver for FebriDx is expected imminently (targeted in March), which would activate the 6‑year U.S. exclusive PHASE distribution deal guaranteeing a minimum USD 317 million in sales to Lumos (PHASE paid a USD 1.0m exclusivity fee in H1 and is expected to prepay USD 5.0m on waiver), and highlighted that FebriDx has Medicare/MAC reimbursement of USD 41.38 per test (seven MACs agreed); BARDA‑funded pediatric work (~USD 6.2m) should add ~20% to the addressable market with the pediatric trial expected to finish by year‑end. Financial guidance reinforced H1 FY26 results: revenue USD 6.1m (products USD 1.7m vs USD 0.8m prior, services USD 4.4m vs USD 5.5m), IP revenue USD 1.0m (vs 2.6m), gross profit USD 4.2m and 68% gross margin, adjusted EBITDA loss USD 1.4m (improved from a USD 4.2m loss in H1 FY24), operating cash flow +USD 0.1m (vs -6.8m), BARDA receipts USD 2.8m, and liquidity support with USD 1.0m drawn on a finance facility (USD 4.0m remaining); management said current manufacturing capacity can meet expected PHASE demand for the first two years but will require investment to scale thereafter.

Lumos Diagnostics Holdings Ltd. Financial Statement Overview

Summary

Financial performance is mixed. The balance sheet is strong with low debt and improved equity, and operating cash flow turned positive. However, these are overshadowed by collapsing gross margins and deep operating losses, indicating poor core profitability.

Income Statement

35Negative

Balance Sheet

65Positive

Cash Flow

45Neutral
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue13.20M13.48M12.50M11.13M10.54M11.63M
Gross Profit-7.73M-7.91M7.91M7.10M5.32M4.46M
EBITDA-11.59M-11.84M-4.73M-5.33M-4.87M―
Net Income-5.04M-5.06M-7.18M-8.59M-8.97M-45.72M
Balance Sheet
Total Assets40.74M40.74M20.81M26.84M25.42M36.94M
Cash, Cash Equivalents and Short-Term Investments15.42M15.42M1.96M6.48M3.02M7.98M
Total Debt5.94M5.94M6.99M8.06M9.79M7.19M
Total Liabilities17.88M17.88M14.65M19.73M15.92M19.05M
Stockholders Equity22.85M22.85M6.16M7.11M9.50M17.89M
Cash Flow
Free Cash Flow-1.52M-1.56M-9.39M848.00K-9.79M-22.39M
Operating Cash Flow970.13K1.04M-9.33M946.00K-9.64M-18.04M
Investing Cash Flow-2.49M-2.59M-53.00K-98.00K4.31M-4.36M
Financing Cash Flow14.99M15.56M5.28M2.63M652.00K-10.92M

Lumos Diagnostics Holdings Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price0.07

Price Trends

50DMA0.09Negative
100DMA0.10Negative
200DMA0.14Negative

Market Momentum

MACD-0.00Negative
RSI43.63Neutral
STOCH71.51Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:LDX, the sentiment is Negative. The current price of 0.07 is above the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.09, and below the 200-day MA of 0.14, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 43.63 is Neutral, neither overbought nor oversold. The STOCH value of 71.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:LDX.

Lumos Diagnostics Holdings Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

AU:LDX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:SHLAU:SHL72OutperformAUD 9.92B16.677.20%5.38%14.40%15.11%
AU:ACLAU:ACL59NeutralAUD 621.11M26.9815.80%3.90%-0.90%-25.09%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:GSSAU:GSS50NeutralAUD 16.35M-1.12-35.10%―-9.10%31.75%
AU:LDXAU:LDX42NeutralAUD 75.10M-7.50-35.89%―1.36%39.13%
AU:BDXAU:BDX39UnderperformAUD 22.20M-2.98-881.94%―743.51%-1.52%

* Healthcare Sector Average

Performance Comparison

-50%0%50%AU:LDXAU:BDXAU:GSSAU:SHLAU:ACLDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AU:LDX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AU:LDXLumos Diagnostics Holdings Ltd.0.07-0.12-62.11%
AU:BDXBCAL Diagnostics Limited0.06-0.03-33.33%
AU:GSSGenetic Signatures Ltd.0.07-0.23-75.33%
AU:SHLSonic Healthcare Limited20.07-1.62-7.45%
AU:ACLAustralian Clinical Labs Ltd3.330.7026.57%

Lumos Diagnostics Holdings Ltd. Corporate Events

Lumos Diagnostics Reports 2026 AGM Voting Results

Nov 13, 2026

Lumos Diagnostics Holdings Limited reported the voting results of its 2026 annual general meeting held on 13 November 2026. All 10 ordinary and special resolutions were carried, including adoption of the remuneration report, director elections, equit...

Lumos Reports FebriDx CLIA Waiver and U.S. Site Expansion

Nov 12, 2026

Lumos Diagnostics develops rapid, point-of-care diagnostic technologies, including proprietary tests for infectious and inflammatory diseases, digital reader platforms, and assay development and manufacturing services. The company said FDA CLIA waive...

Lumos Diagnostics Outlines Q1 FY27 Update with Strong Investor Disclaimers

Oct 26, 2026

Lumos Diagnostics Holdings Ltd. has released its Q1 FY27 results and commercial update via an investor webinar, reiterating its role as a listed medical diagnostics company providing rapid point-of-care testing solutions to healthcare markets. The up...

Lumos Diagnostics Boosts FebriDx Sales as U.S. Rollout Accelerates

Oct 26, 2026

Lumos Diagnostics reported first-quarter FY27 revenue of about US$2.0 million, down 39 per cent year on year amid lower services income and the absence of a prior one‑off exclusivity fee, but product revenue surged 224 per cent, led by a 351 per cent...

Lumos Diagnostics Seeks ASX Quotation for 16.5 Million New Shares

Oct 19, 2026

Lumos Diagnostics Holdings Ltd. has applied for quotation of 16,500,000 new fully paid ordinary shares on the ASX, with the securities issued on 19 October 2026. The move enlarges the company’s listed share base, signalling an expansion of its capita...

Lumos Diagnostics Sets Q1 FY27 Results Release and Investor Webinar

Oct 19, 2026

Lumos Diagnostics Holdings Ltd has scheduled the release of its financial results for the quarter ended 30 September 2026 on 27 October 2026, underscoring continued transparency with investors as it enters FY27. On the same day, the company will host...

Lumos Diagnostics Discloses Final Director Interest as Mehren Departs Board

Oct 13, 2026

Lumos Diagnostics Holdings Ltd has reported a change in its board composition, with director Lawrence Mehren ceasing to serve on the board as of 12 October 2026. The company disclosed that Mehren holds 80,000 fully paid ordinary shares as a registere...

Lumos Diagnostics Appoints New Director With No Current Shareholding

Oct 13, 2026

Lumos Diagnostics Holdings Ltd has notified the ASX of the appointment of Aizaz Syed as a director effective 12 October 2026. The disclosure was made under listing rule 3.19A.1 and relevant sections of the Corporations Act, highlighting the company’s...

Lumos Diagnostics Sets 2026 AGM as Fully Virtual Event

Oct 12, 2026

Lumos Diagnostics Holdings Ltd. has called its Annual General Meeting for 13 November 2026, to be conducted virtually via a Zoom webinar, reflecting its continued use of technology to engage a geographically dispersed shareholder base. The board has...

Lumos Diagnostics Reshapes Board as Major Shareholder Gains Representation

Oct 12, 2026

Lumos Diagnostics has appointed Aizaz Syed as a Non-Executive Director, representing its largest shareholder Tenmile Ventures Pty Ltd., as part of changes to its board. Syed brings extensive healthcare investing and corporate strategy experience, ref...

Lumos Diagnostics Options Lapse, Simplifying Capital Structure

Oct 8, 2026

Lumos Diagnostics has notified the market of the cessation of several classes of options, including series expiring in August 2026 and December 2027, after they lapsed without being exercised or were otherwise terminated. The expiry of these options...

Lumos Diagnostics Issues New Shares on Employee Option Exercise, Confirms Compliance

Sep 29, 2026

Lumos Diagnostics Holdings Ltd., based in Melbourne, operates in the point-of-care diagnostics industry, providing rapid and cost-effective test technology for healthcare professionals. It develops and manufactures customised assays, proprietary digi...

Lumos Diagnostics Issues New Shares After Ryder Capital Option Exercise

Sep 15, 2026

Lumos Diagnostics has issued 26,098,017 fully paid ordinary shares following the exercise of an equivalent number of unquoted options by Ryder Capital Ltd, expanding its share capital without a traditional disclosure document. The company affirmed it...

Lumos Diagnostics Seeks ASX Quotation for 26 Million New Shares

Sep 15, 2026

Lumos Diagnostics Holdings Ltd. has applied for quotation of 26,098,017 new ordinary fully paid shares on the Australian Securities Exchange, effective September 15, 2026. The move expands the company’s quoted share base and may influence its capital...

Lumos accelerates U.S. FebriDx rollout across major urgent care networks

Sep 14, 2026

Lumos Diagnostics is accelerating the U.S. rollout of its FebriDx point-of-care test, expanding live sites to 215 across 26 states and increasing actively evaluated sites to 405 within priority urgent care groups. The company is executing a structure...

Lumos Diagnostics Issues New Shares on Employee Option Exercises and Confirms Regulatory Compliance

Sep 1, 2026

Lumos Diagnostics has issued a total of 303,474 fully paid ordinary shares following the exercise of unquoted employee options, including 76,480 shares from options exercised at $0.0576 and 226,994 shares from a cashless option exercise. The company...

Lumos Diagnostics Seeks Quotation for Additional ASX Shares

Sep 1, 2026

Lumos Diagnostics Holdings Ltd. has applied for quotation of 303,474 new ordinary fully paid shares on the ASX, with an issue date of 31 August 2026. The additional securities, arising from the exercise or conversion of existing instruments, modestly...

Lumos Director Doug Ward Increases On‑Market Shareholding

Sep 1, 2026

Lumos Diagnostics has reported a change in the holdings of director Doug Ward, who increased his stake in the company through an on‑market purchase. Ward acquired 202,131 fully paid ordinary shares for approximately $21,224, lifting his direct shareh...

Lumos Diagnostics Files 2026 Corporate Governance Statement with ASX

Aug 26, 2026

Lumos Diagnostics Holdings Limited has lodged its corporate governance statement for the financial year ended 30 June 2026 with the ASX and made it available via its investor website. The statement outlines the extent to which the company complies wi...

Lumos Diagnostics’ FY26 Milestones Expand FebriDx U.S. Market to Over US$1 Billion

Aug 26, 2026

Lumos reported a landmark FY26 marked by major regulatory and commercial milestones that significantly expand the U.S. opportunity for its FebriDx test. The company secured an exclusive six-year U.S. distribution agreement with PHASE Scientific value...

Lumos Diagnostics Highlights Point-of-Care Innovation in 2026 Annual Report

Aug 26, 2026

Lumos Diagnostics’ 2026 annual report underscores its commitment to innovation in point-of-care testing, highlighting its role in delivering real-time diagnostic information at the patient’s location. By emphasizing world-leading technologies and rap...

Lumos Diagnostics Narrows Annual Loss as Revenue Grows but Going-Concern Risks Persist

Aug 26, 2026

Lumos Diagnostics Holdings Limited reported a 6.4% increase in revenue to US$13.19 million for the year ended 30 June 2026, signaling modest growth in its diagnostics business. The company’s net tangible assets per ordinary security improved from neg...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 29, 2026